US 12,497,458 B2Granted

Anti-GAL3 antibodies and uses thereof

AssigneeTrueBinding, Inc.

InventorsDongxu Sun, Yan Wang, Yinan Wu, Catherine A. Gordon, Samuel A. F. Williams

Life of this patent

Estimating the term…

Abstract

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Claims5

Dependent claims

An anti-GAL3 antibody or binding fragment thereof, wherein the anti-Gal3 antibody or binding fragment thereof comprises (1) a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3;

and (2) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3, wherein
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
37, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
65, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
93, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
121, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
177;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
38, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
66, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
94, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
122, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
178;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
39, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
67, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
95, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
123, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
179;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
40, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
68, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
96, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
124, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
180;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
41, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
69, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
97, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
125, the VL-CDR2 comprises an amino acid sequence comprising YTS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
181;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
42, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
70, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
98, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
126, the VL-CDR2 comprises an amino acid sequence comprising KVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
182;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
43, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
71, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
99, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
127, the VL-CDR2 comprises an amino acid sequence comprising HAT, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
183;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
44, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
72, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
100, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
128, the VL-CDR2 comprises an amino acid sequence comprising LLS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
184;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
45, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
73, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
101, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
129, the VL-CDR2 comprises an amino acid sequence comprising GAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
185;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
46, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
74, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
102, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
130, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
186;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
47, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
75, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
103, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
131, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
187;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
48, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
76, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
104, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
132, the VL-CDR2 comprises an amino acid sequence comprising KVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
188;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
49, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
77, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
105, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
133, the VL-CDR2 comprises an amino acid sequence comprising KAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
189;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
50, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
78, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
106, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
134, the VL-CDR2 comprises an amino acid sequence comprising YAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
190;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
51, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
79, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
107, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
135, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
191;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
52, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
80, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
108, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
136, the VL-CDR2 comprises an amino acid sequence comprising KAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
192;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
54, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
82, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
110, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
138, the VL-CDR2 comprises an amino acid sequence comprising YAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
194;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
55, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
83, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
111, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
139, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
195;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
56, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
84, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
112, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
140, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
196;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
57, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
85, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
113, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
141, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
197;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
58, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
86, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
114, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
142, the VL-CDR2 comprises an amino acid sequence comprising LVC, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
198;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
59, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
87, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
115, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
143, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
199;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
61, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
89, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
117, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
145, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
201;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
63, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
91, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
119, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
147, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
203;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
64, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
92, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
120, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
148, the VL-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
176, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
204.

173 more elements

An anti-GAL3 antibody or binding fragment thereof, wherein the antibody or binding fragment comprises:

a heavy chain sequence comprising SEQ ID NO:
205 and a light chain sequence comprising SEQ ID NO:
233;
or
a heavy chain sequence comprising SEQ ID NO:
206 and a light chain sequence comprising SEQ ID NO:
234;
or
a heavy chain sequence comprising SEQ ID NO:
207 and a light chain sequence comprising SEQ ID NO:
235;
or
a heavy chain sequence comprising SEQ ID NO:
208 and a light chain sequence comprising SEQ ID NO:
236;
or
a heavy chain sequence comprising SEQ ID NO:
209 and a light chain sequence comprising SEQ ID NO:
237;
or
a heavy chain sequence comprising SEQ ID NO:
210 and a light chain sequence comprising SEQ ID NO:
238;
or
a heavy chain sequence comprising SEQ ID NO:
211 and a light chain sequence comprising SEQ ID NO:
239;
or
a heavy chain sequence comprising SEQ ID NO:
212 and a light chain sequence comprising SEQ ID NO:
240;
or
a heavy chain sequence comprising SEQ ID NO:
213 and a light chain sequence comprising SEQ ID NO:
241;
or
a heavy chain sequence comprising SEQ ID NO:
214 and a light chain sequence comprising SEQ ID NO:
242;
or
a heavy chain sequence comprising SEQ ID NO:
215 and a light chain sequence comprising SEQ ID NO:
243;
or
a heavy chain sequence comprising SEQ ID NO:
216 and a light chain sequence comprising SEQ ID NO:
244;
or
a heavy chain sequence comprising SEQ ID NO:
217 and a light chain sequence comprising SEQ ID NO:
245;
or
a heavy chain sequence comprising SEQ ID NO:
218 and a light chain sequence comprising SEQ ID NO:
246;
or
a heavy chain sequence comprising SEQ ID NO:
219 and a light chain sequence comprising SEQ ID NO:
247;
or
a heavy chain sequence comprising SEQ ID NO:
220 and a light chain sequence comprising SEQ ID NO:
248;
or
a heavy chain sequence comprising SEQ ID NO:
222 and a light chain sequence comprising SEQ ID NO:
250;
or
a heavy chain sequence comprising SEQ ID NO:
223 and a light chain sequence comprising SEQ ID NO:
251;
or
a heavy chain sequence comprising SEQ ID NO:
224 and a light chain sequence comprising SEQ ID NO:
252;
or
a heavy chain sequence comprising SEQ ID NO:
225 and a light chain sequence comprising SEQ ID NO:
253;
or
a heavy chain sequence comprising SEQ ID NO:
226 and a light chain sequence comprising SEQ ID NO:
254;
or
a heavy chain sequence comprising SEQ ID NO:
227 and a light chain sequence comprising SEQ ID NO:
255;
or
a heavy chain sequence comprising SEQ ID NO:
229 and a light chain sequence comprising SEQ ID NO:
257;
or
a heavy chain sequence comprising SEQ ID NO:
230 and a light chain sequence comprising SEQ ID NO:
258;
or
a heavy chain sequence comprising SEQ ID NO:
231 and a light chain sequence comprising SEQ ID NO:
259;
or
a heavy chain sequence comprising SEQ ID NO:
232 and a light chain sequence comprising SEQ ID NO:
260.

100 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/813,578Filed 19 Jul 2022 · continuation
Priority: 30 Jan 2019
Published: US 2022/0002420 A11 Dec 2022
Granted: 16 Dec 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 35/00
Antineoplastic agents
A61P 35/04
Antineoplastic agents: specific for metastasis

Family

Application62/798,945Us provisional application · filed 30 Jan 2019
Application62/798,949Us provisional application · filed 30 Jan 2019
PCT/US2020/015692Parent of this continuation · filed 29 Jan 2020
Application17/384,542Parent of this continuation · filed 23 Jul 2021
US 2022/0380473 A1Pre-grant publication · published 1 Dec 2022
US 11,427,638 B2Parent of this continuation
US 2022/0002420 A1Published application
US 12,497,458 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

and (2) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3, wherein
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
37, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
65, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
93, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
121, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
177;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
38, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
66, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
94, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
122, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
178;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
39, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
67, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
95, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
123, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
179;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
40, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
68, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
96, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
124, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
180;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
41, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
69, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
97, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
125, the VL-CDR2 comprises an amino acid sequence comprising YTS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
181;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
42, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
70, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
98, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
126, the VL-CDR2 comprises an amino acid sequence comprising KVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
182;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
43, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
71, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
99, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
127, the VL-CDR2 comprises an amino acid sequence comprising HAT, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
183;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
44, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
72, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
100, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
128, the VL-CDR2 comprises an amino acid sequence comprising LLS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
184;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
45, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
73, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
101, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
129, the VL-CDR2 comprises an amino acid sequence comprising GAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
185;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
46, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
74, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
102, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
130, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
186;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
47, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
75, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
103, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
131, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
187;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
48, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
76, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
104, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
132, the VL-CDR2 comprises an amino acid sequence comprising KVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
188;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
49, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
77, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
105, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
133, the VL-CDR2 comprises an amino acid sequence comprising KAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
189;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
50, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
78, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
106, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
134, the VL-CDR2 comprises an amino acid sequence comprising YAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
190;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
51, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
79, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
107, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
135, the VL-CDR2 comprises an amino acid sequence comprising LVS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
191;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
52, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
80, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
108, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
136, the VL-CDR2 comprises an amino acid sequence comprising KAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
192;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
54, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
82, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
110, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
138, the VL-CDR2 comprises an amino acid sequence comprising YAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
194;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
55, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
83, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
111, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
139, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
195;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
56, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
84, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
112, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
140, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
196;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
57, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
85, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
113, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
141, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
197;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
58, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
86, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
114, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
142, the VL-CDR2 comprises an amino acid sequence comprising LVC, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
198;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
59, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
87, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
115, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
143, the VL-CDR2 comprises an amino acid sequence comprising WAS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
199;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
61, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
89, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
117, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
145, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
201;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
63, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
91, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
119, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
147, the VL-CDR2 comprises an amino acid sequence comprising RMS, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
203;
or
the VH-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
64, the VH-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
92, the VH-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
120, the VL-CDR1 comprises an amino acid sequence comprising SEQ ID NO:
148, the VL-CDR2 comprises an amino acid sequence comprising SEQ ID NO:
176, the VL-CDR3 comprises an amino acid sequence comprising SEQ ID NO:
204.

173 more elements

Facts

Application

17/813,578Filed 19 Jul 2022 · continuation

Priority

30 Jan 2019

Published

US 2022/0002420 A11 Dec 2022

Granted

16 Dec 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 35/00
Antineoplastic agents
A61P 35/04
Antineoplastic agents: specific for metastasis

Family

Application62/798,945Us provisional application · filed 30 Jan 2019

Application62/798,949Us provisional application · filed 30 Jan 2019

PCT/US2020/015692Parent of this continuation · filed 29 Jan 2020

Application17/384,542Parent of this continuation · filed 23 Jul 2021

US 2022/0380473 A1Pre-grant publication · published 1 Dec 2022

US 11,427,638 B2Parent of this continuation

US 2022/0002420 A1Published application

US 12,497,458 B2This patent

From the US filing history. Foreign family members aren’t listed.